Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.6

From GxPlex

Revision as of 17:29, 15 July 2026 by imported>GxPlexBot (Import from GxPlex Excel)
Jump to: navigation, search



Document information
Reference ICH ICH E6 Guideline R3 (2025)
Validity area ICH
Scope(s) HM
Document name ICH E6 Guideline
Version / Revision R3 (2025)
Status Current
Document type International guideline
Language(s) EN
Description GUIDELINE FOR GOOD CLINICAL PRACTICE
Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 6 — Unit 6.1.2
Scope G
Document part III. Annex 1

2.6

Language EN
Original entry by Florian Adragna
Contributors
Tags Early termination, Temporary halt, Investigator responsibilities, Trial participant
Comment Investigator obligations on premature termination or suspension

Content

2. INVESTIGATOR [...] 2.6 Premature Termination or Suspension of a Trial 2.6.1 If the trial is prematurely terminated or suspended for any reason, the investigator/institution should promptly inform the trial participants and should ensure appropriate therapy and follow-up for the participants.

2.6.2Where the investigator terminates or suspends their involvement in a trial without prior agreement by the sponsor, the investigator should promptly inform the institution, where applicable, the sponsor, the IRB/IEC and the regulatory authorities in accordance with applicable regulatory requirements and should provide a detailed explanation of the reasons.

2.6.3 If the sponsor terminates or suspends a trial, the investigator/institution or the sponsor, in accordance with applicable regulatory requirement(s), should promptly inform the IRB/IEC and the regulatory authorities and should provide an appropriate explanation (see section 3.17.1).

2.6.4 If the IRB/IEC terminates or suspends its approval/favourable opinion of a trial (see sections 1.2.3 and 1.4.9), the investigator should inform the institution, where applicable, and the investigator/institution should promptly notify the sponsor.